RICHMOND, British Columbia, Oct. 25, 2006 (PRIMEZONE) -- BioCurex Inc. (OTCBB:BOCX) announced today that it has presented its first set of results using a colorimetric version of its RECAF(tm) blood test for cancer detection at the annual meeting of the International Society for Oncofetal Biology and Medicine in Pasadena, CA. The results exhibited that this colorimetric version of BioCurex's RECAF test detected more than twice the amount of cancers than the most widely used cancer detection test utilized today -- the PSA test.
